Celldex Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Celldex Therapeutics

08/08/2023 23:01

* Celldex Therapeutics Inc  CLDX.OQ  reported a quarterly
adjusted
loss of 65 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 67 cents per share.
    * Revenue rose 64.4% to $268.00 thousand from a year ago;
analysts
expected $528.00 thousand. 
    * Celldex Therapeutics Inc's reported EPS for the quarter
was a
loss of 65 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Celldex Therapeutics Inc shares had fallen by 3.8% this
quarter and lost 26.7% so far this year.
    * The company reported a quarterly loss of $30.5 million.
    * Wall Street's median 12-month price target for Celldex
Therapeutics Inc is $65.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.67          -0.65          Beat
 Mar. 31 2023      -0.63          -0.62          Beat
 Dec. 31 2022      -0.59          -0.56          Beat
 Sep. 30 2022      -0.58          -0.57          Beat